"A Phase 3, Global, Randomized, Double-Blind Trial of Tazemetostat in Combination with Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma"

Administered By

Duke Cancer Institute

Awarded By

Epizyme, Inc

Contributors

Riedel, Richard Francis Principal Investigator

Start/End

August 6, 2020 - July 31, 2025